OrganOx Secures $142M to Revolutionize Organ Transplantation
Deal News | Feb 28, 2025 | La Maison Partners SASU
OrganOx, a pioneer in medical technologies aiming to revolutionize organ transplantation, announced the successful closure of a $142 million equity funding round. The round was led by Lauxera Capital Partners, BGF, and HealthQuest Capital. OrganOx's technology has enabled over 5,000 liver transplants and reduced liver rejection rates by 50%, while increasing transplant success rates by 20% compared to traditional cold storage methods. The strategic funding will accelerate OrganOx's expansion and reinforce its leadership in the transplantation field. La Maison Partners SASU expressed pride in supporting this visionary company alongside its investors and management team.
Sectors
- Healthcare - Medical Technology
- Finance - Private Equity
Geography
- United Kingdom – OrganOx is a UK-based company specializing in medical technologies.
- United States – BGF and HealthQuest Capital are key investors, indicating significant transatlantic investment activity.
Industry
- Healthcare - Medical Technology – OrganOx operates in the medical technology sector, focusing on innovations that improve transplant outcomes.
- Finance - Private Equity – The involvement of private equity firms like Lauxera Capital Partners indicates a significant transaction within the finance sector.
Financials
- $142 million – The amount raised by OrganOx in its recent equity funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| OrganOx | Target Company | Company | A medical technology company focused on improving outcomes in organ transplantation. |
| La Maison Partners SASU | Private Equity Firm | Company | A private equity firm involved in the funding of OrganOx. |
| Lauxera Capital Partners | Lead Investor | Company | A private equity firm leading OrganOx's funding round. |
| BGF | Investor | Company | A growth capital investor contributing to OrganOx's funding. |
| HealthQuest Capital | Investor | Company | A healthcare-focused investment firm participating in OrganOx's funding. |